Skip to main content
Transplanted human multipotent stromal cells reduce acute tongue fibrosis in rats.
- Author(s): Vahabzadeh-Hagh, Andrew M;
- Goel, Alexander N;
- Frederick, John W;
- Berke, Gerald S;
- Long, Jennifer L
- et al.
Published Web Locationhttps://doi.org/10.1002/lio2.202
BackgroundTongue fibrosis resulting from head and neck cancer, surgery, radiation, chemotherapy, or a combination thereof devastates one's quality of life. Therapeutic options are limited. Here we investigate human bone marrow-derived multipotent stromal cells (MSC) as a novel injectable treatment for post-injury tongue fibrosis.
MethodsMSCs were grown in culture. Eighteen athymic rats underwent unilateral partial glossectomy. After two weeks for scar formation, a single injection was performed in the tongue scar. Three treatment groups were studied: low and high concentration MSC, and control media injection. Tongues were harvested for evaluation at three weeks post-treatment.
ResultsDense fibrosis was achieved in control animals at five weeks. High concentration MSC reduced cross sectional scar burden (P = .007) and pathologic score for inflammation and fibrosis.
ConclusionThis study establishes the feasibility of a novel rodent tongue fibrosis model, and begins to assess the utility of human MSCs to reduce scar burden.
Level of evidenceN/a.
For improved accessibility of PDF content, download the file to your device.